Upstream Bio(UPB)

Focus: Upstream Bio is a public biotech company founded in 2022 focused on therapies for allergic and inflammatory conditions, with a current headcount of 51-200 employees and public market listing. The company is in early clinical stages with no commercial revenue to date.

Oncology Immunology

Profile data last refreshed 15h ago · AI intelligence enriched 2mo ago

Funding Stage

PUBLIC

Employees

51-200

Open Jobs

About Upstream Bio

AI assessmentNot Hiring

No open roles listed right now. Follow Upstream Bio to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

3/9 — Basic

Company HealthSolid

Pipeline

Early-stage

6 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Revenue

$2M

FY2025

Pipeline & Clinical Trials

UPB-101

Healthy

PHASE_1

UPB-101

Asthma

PHASE_1

Verekitug

Chronic Obstructive Pulmonary Disease

Help build intelligence for Upstream Bio

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Significant cash position of $326M as of FY2025 enables extended runway and pipeline execution without immediate funding pressure
Public company status provides liquidity and traditional pharma career infrastructure rare for 2022-founded startups
Focus on high-unmet-need immunology/allergic conditions (severe asthma, CRSwNP, COPD) with multiple shots on goal

Watch Out For

Extremely early pipeline (2 Phase 1 programs, 4 Phase 2 programs) with zero Phase 3 programs and no near-term regulatory catalysts
Dramatically increased R&D burn ($32M to $63M YoY) against flat $2M revenue signals unsustainable cash consumption trajectory
Currently zero open job listings suggests potential hiring freeze or severe stage-gate constraints despite public status

Generated by Claude from Upstream Bio's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Verekitug

Severe Asthma

PHASE_2

Verekitug

Severe Asthma

PHASE_2